{"nctId":"NCT00267189","briefTitle":"RESCUE Study - Everolimus in Liver Transplantation Recipients With Renal Insufficiency","startDateStruct":{"date":"2005-11"},"conditions":["Liver Transplantation"],"count":145,"armGroups":[{"label":"Reduced CNI dose + everolimus ± steroids","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Everolimus","Drug: Calcineurin inhibitors (CNI)","Drug: Steroids"]},{"label":"CNI continuation ± MPA/AZA ± Steroids","type":"EXPERIMENTAL","interventionNames":["Drug: Calcineurin inhibitors (CNI)","Drug: Mycophenolate acid (MPA)/ Azathioprine (AZA)","Drug: Steroids"]}],"interventions":[{"name":"Everolimus","otherNames":["Certican","RAD001","Neoral®/Prograf®"]},{"name":"Calcineurin inhibitors (CNI)","otherNames":["Neoral/Prograf"]},{"name":"Mycophenolate acid (MPA)/ Azathioprine (AZA)","otherNames":["Myfortic/Cellecept"]},{"name":"Steroids","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion criteria\n\n* Male or female 18 - 70 years old\n* Patient who has undergone a primary liver transplantation 12 to 60 months ago from a cadaveric or a living donor\n* Patient with a calculated GFR ≤ 60 and ≥ 20mL/min\n* Patient receiving tacrolimus with C0-h level ≥ 3 and ≤ 8 ng/mL or Neoral® with C0-h level ≥ 50 and ≤ 150 ng/mL or with C2-h level ≥ 250 ng/mL and ≤ 650 ng/mL with or without any of the following (MPA or AZA or steroids)\n* Patient willing and capable of giving written informed consent for study participation and able to participate in the study for 6 months\n* Patient in whom an allograft biopsy will not be contraindicated\n* Female capable of becoming pregnant must have a negative pregnancy test prior to randomization and are required to practice a medically approved method of birth control for the duration of the study\n\nExclusion criteria\n\n* Recipient of multiple solid organ transplants\n* Patient on dialysis\n* Patient with an identifiable cause of renal dysfunction other than CNI toxicity\n* Patient with proteinuria ≥ 1.0 g/24h\n* Patient with any acute rejection within 6 months prior to randomization\n* Patient with platelet count of ≤ 50,000/mm³ or white blood cell count of ≤ 2,000/mm³ or hemoglobin value ≤ 8 g/dL\n* Undergone a liver transplantation for a hepatocellular carcinoma with sign of recurrence;\n* Severe graft dysfunction;\n* HCV positive patient who needs an active anti-viral treatment\n* HIV positive patient\n* Patient who is breast feeding\n* Patient with a current severe systemic infection\n* Patient who has received an unlicensed drug or therapy within one month prior to study entry\n* Presence of any hypersensitivity to drugs similar to everolimus (e.g. macrolides)\n* Use of any other immunosuppressive drugs than tacrolimus/cyclosporine microemulsion, steroids, azathioprine and mycophenolic acid\n\nAdditional protocol-defined inclusion/exclusion criteria may apply.","sex":"ALL","minimumAge":"18 Years","maximumAge":"70 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Mean Change From Baseline in Cockcroft-Gault Calculated Creatinine Clearance (CrCl)","description":"The primary variable was renal function assessed by calculated creatinine clearance using the Cockcroft-Gault formula, and was assessed at all visits.\n\nCrCl\\[mL/min\\] = (140 - A) \\* W / (72 \\* C) \\* R. Where A is age at sample date \\[years\\], W is body weight at specific visit \\[kg\\], C is the serum concentration of creatinine \\[mg/dL\\], R = 1 if the patient is male and = 0.85 if female.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.99","spread":"10.25"},{"groupId":"OG001","value":"2.26","spread":"7.79"}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients With Efficacy Failure (Biopsy Proven Acute Rejection [BPAR], Graft Loss or Death)","description":"The composite efficacy failure endpoint encompasses at least one of: biopsy proven acute rejection, graft loss, or death for the patient. BPAR was defined as a clinically suspected acute rejection confirmed by biopsy. Acute rejection episodes were recorded as Liver Allograft Rejection. The allograft was presumed to be lost if a patient had a liver retransplant or died.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.8","spread":null},{"groupId":"OG001","value":"1.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.4","spread":null},{"groupId":"OG001","value":"1.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.4","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Patients With Discontinuation of Study Medication","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"18","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":18,"n":72},"commonTop":["Hypercholesterolaemia","Leukopenia","Aphthous stomatitis","Nausea","Nasopharyngitis"]}}}